PCH
BBIO icon

Polar Capital Holdings’s BridgeBio Pharma BBIO Stock Holding History

Polar Capital Holdings’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$154M Sell
2,063,609
-455,697
-18% -$31.9M 0.36% 62
2026
Q1 		$187M Buy
2,519,306
+1,219,960
+94% +$88.4M 0.66% 42
2025
Q4 		$99.4M Buy
1,299,346
+318,288
+32% +$20.9M 0.38% 69
2025
Q3 		$51M Buy
+981,058
New +$47.8M 0.25% 97

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Polar Capital Holdings's BBIO Position: Q2 2026 in Review

Polar Capital Holdings reduced its BridgeBio Pharma (BBIO) stake by 18% in Q2 2026, selling an estimated $31.9M and leaving 2,063,609 shares worth $154M. The position accounts for 0.36% of the portfolio, ranked #62.

Polar Capital Holdings first reported a position in BBIO in Q3 2025 and has held it in 4 quarters since. The position peaked at $187M in Q1 2026. 475 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Polar Capital Holdings held 2,063,609 shares of BridgeBio Pharma worth $154M as of Q2 2026.
  • Polar Capital Holdings sold 455,697 BridgeBio Pharma shares in Q2 2026, an estimated $31.9M.
  • BridgeBio Pharma made up 0.36% of Polar Capital Holdings's portfolio in Q2 2026, its #62 holding.
  • Polar Capital Holdings first reported a position in BridgeBio Pharma in Q3 2025 and has held it in 4 quarters since.
  • Polar Capital Holdings's BridgeBio Pharma position peaked at $187M in Q1 2026.
  • 475 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Polar Capital Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.